Consultation on clinical commissioning policy: Metreleptin for congenital leptin deficiency

Overview

NHS England has launched a 30 day consultation on a policy proposition to treat congenital leptin deficiency with metreleptin. Metreleptin is an artificial form of leptin. It replaces the hormone which is missing. Patients who have congenital leptin deficiency return to normal weight when treated with metreleptin. Treatment with metreleptin leads to either improvement or resolution of many of the comorbidities associated with obesity caused by congenital leptin deficiency.

Related documents

• Draft policy
• Stakeholder engagement report
• Impact assessment
• CPAG summary report
• Clinical panel report
• Evidence review